PubMed

Cost-effectiveness of tipranavir versus comparator protease inhibitor regimens in HIV infected patients previously exposed to antiretroviral therapy in the Netherlands.

Hubben GA, Bos JM, Veltman-Starkenburg CA, Stegmeijer S, Finnern HW, Kappelhoff BS, Simpson KN, Tramarin A, Postma MJ.

Cost Eff Resour Alloc. 2007 Nov 22;5:15.PMID: 18034881 [PubMed]Free PMC ArticleFree textRelated citations

Cost-effectiveness of tipranavir in treatment-experienced HIV patients in the United States.

Simpson KN, Roberts G, Hicks CB, Finnern HW.

HIV Clin Trials. 2008 Jul-Aug;9(4):225-37.PMID: 18753117 [PubMed - indexed for MEDLINE]Free ArticleRelated citations

Ritonavir-boosted tipranavir demonstrates superior efficacy to ritonavir-boosted protease inhibitors in treatment-experienced HIV-infected patients: 24-week results of the RESIST-2 trial.

Cahn P, Villacian J, Lazzarin A, Katlama C, Grinsztejn B, Arasteh K, López P, Clumeck N, Gerstoft J, Stavrianeas N, Moreno S, Antunes F, Neubacher D, Mayers D.

Clin Infect Dis. 2006 Nov 15;43(10):1347-56. Epub 2006 Oct 17.PMID: 17051504 [PubMed - indexed for MEDLINE]Related citations

Efficacy of the protease inhibitors tipranavir plus ritonavir in treatment-experienced patients: 24-week analysis from the RESIST-1 trial.

Gathe J, Cooper DA, Farthing C, Jayaweera D, Norris D, Pierone G Jr, Steinhart CR, Trottier B, Walmsley SL, Workman C, Mukwaya G, Kohlbrenner V, Dohnanyi C, McCallister S, Mayers D; RESIST-1 Study Group.

Clin Infect Dis. 2006 Nov 15;43(10):1337-46. Epub 2006 Oct 17.PMID: 17051503 [PubMed - indexed for MEDLINE]Related citations

Cost effectiveness of lopinavir/ritonavir tablets compared with atazanavir plus ritonavir in antiretroviral-experienced patients in the UK, France, Italy and Spain.

Simpson KN, Jones WJ, Rajagopalan R, Dietz B.

Clin Drug Investig. 2007;27(12):807-17.PMID: 18020538 [PubMed - indexed for MEDLINE]Related citations

Darunavir: a review of its use in the management of HIV infection in adults.

McKeage K, Perry CM, Keam SJ.

Drugs. 2009;69(4):477-503. doi: 10.2165/00003495-200969040-00007. Review.PMID: 19323590 [PubMed - indexed for MEDLINE]Related citations

Adefovir dipivoxil and pegylated interferon alfa-2a for the treatment of chronic hepatitis B: a systematic review and economic evaluation.

Shepherd J, Jones J, Takeda A, Davidson P, Price A.

Health Technol Assess. 2006 Aug;10(28):iii-iv, xi-xiv, 1-183. Review.PMID: 16904047 [PubMed - indexed for MEDLINE]Free ArticleRelated citations

Health-related quality of life and tolerability in treatment-experienced HIV-1-infected patients on tipranavir versus comparator regimens.

Huang IC, Wu AW, Finnern HW, Thijs H, Gathe JC, Fairclough DL.

Antivir Ther. 2008;13(1):15-25.PMID: 18389895 [PubMed - indexed for MEDLINE]Related citations

Cost effectiveness of lopinavir/ritonavir compared with atazanavir in antiretroviral-naive patients: modelling the combined effects of HIV and heart disease.

Simpson KN, Luo MP, Chumney EC, King MS, Brun S.

Clin Drug Investig. 2007;27(1):67-74.PMID: 17177581 [PubMed - indexed for MEDLINE]Related citations

Cost effectiveness of lopinavir/ritonavir compared with atazanavir plus ritonavir in antiretroviral-experienced patients in the US.

Simpson KN, Jones WJ, Rajagopalan R, Dietz B.

Clin Drug Investig. 2007;27(7):443-52. Erratum in: Clin Drug Investig. 2007;27(8):564. PMID: 17563124 [PubMed - indexed for MEDLINE]Related citations

Cost-efficacy comparison among three antiretroviral regimens in HIV-1 infected, treatment-experienced patients.

Ruof J, Dusek A, DeSpirito M, Demasi RA.

Clin Drug Investig. 2007;27(7):469-79.PMID: 17563127 [PubMed - indexed for MEDLINE]Related citations

Durable efficacy of tipranavir-ritonavir in combination with an optimised background regimen of antiretroviral drugs for treatment-experienced HIV-1-infected patients at 48 weeks in the Randomized Evaluation of Strategic Intervention in multi-drug reSistant patients with Tipranavir (RESIST) studies: an analysis of combined data from two randomised open-label trials.

Hicks CB, Cahn P, Cooper DA, Walmsley SL, Katlama C, Clotet B, Lazzarin A, Johnson MA, Neubacher D, Mayers D, Valdez H; RESIST investigator group.

Lancet. 2006 Aug 5;368(9534):466-75.PMID: 16890833 [PubMed - indexed for MEDLINE]Related citations

Relative antiviral efficacy of ritonavir-boosted darunavir and ritonavir-boosted tipranavir vs. control protease inhibitor in the POWER and RESIST trials.

Hill A, Moyle G.

HIV Med. 2007 May;8(4):259-64.PMID: 17461854 [PubMed - indexed for MEDLINE]Related citations

The clinical effectiveness and cost-effectiveness of cardiac resynchronisation (biventricular pacing) for heart failure: systematic review and economic model.

Fox M, Mealing S, Anderson R, Dean J, Stein K, Price A, Taylor RS.

Health Technol Assess. 2007 Nov;11(47):iii-iv, ix-248. Review.PMID: 17999842 [PubMed - indexed for MEDLINE]Free ArticleRelated citations

Topotecan, pegylated liposomal doxorubicin hydrochloride and paclitaxel for second-line or subsequent treatment of advanced ovarian cancer: a systematic review and economic evaluation.

Main C, Bojke L, Griffin S, Norman G, Barbieri M, Mather L, Stark D, Palmer S, Riemsma R.

Health Technol Assess. 2006 Mar;10(9):1-132. iii-iv. Review.PMID: 16545208 [PubMed - indexed for MEDLINE]Free ArticleRelated citations

When to initiate highly active antiretroviral therapy in sub-Saharan Africa? A South African cost-effectiveness study.

Badri M, Cleary S, Maartens G, Pitt J, Bekker LG, Orrell C, Wood R.

Antivir Ther. 2006;11(1):63-72.PMID: 16518961 [PubMed - indexed for MEDLINE]Related citations

A rapid and systematic review of the clinical effectiveness and cost-effectiveness of paclitaxel, docetaxel, gemcitabine and vinorelbine in non-small-cell lung cancer.

Clegg A, Scott DA, Sidhu M, Hewitson P, Waugh N.

Health Technol Assess. 2001;5(32):1-195. Review.PMID: 12065068 [PubMed - indexed for MEDLINE]Free ArticleRelated citations

Cost-effectiveness of lopinavir/ritonavir versus nelfinavir as the first-line highly active antiretroviral therapy regimen for HIV infection.

Simpson KN, Luo MP, Chumney E, Sun E, Brun S, Ashraf T.

HIV Clin Trials. 2004 Sep-Oct;5(5):294-304.PMID: 15562370 [PubMed - indexed for MEDLINE]Free ArticleRelated citations

The effectiveness and cost-effectiveness of carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma: a systematic review and economic evaluation.

Garside R, Pitt M, Anderson R, Rogers G, Dyer M, Mealing S, Somerville M, Price A, Stein K.

Health Technol Assess. 2007 Nov;11(45):iii-iv, ix-221. Review.PMID: 17999840 [PubMed - indexed for MEDLINE]Free ArticleRelated citations

Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.

Plosker GL, Figgitt DP.

Pharmacoeconomics. 2004;22(6):389-411. Review.PMID: 15099124 [PubMed - indexed for MEDLINE]Related citations